# CorMedix Inc. (CRMD)

> CorMedix Inc. (CRMD) trades at $4.82 (+3.43%) as of 7:30:04 PM EST on Nov 16, 2026, -33.61% over the past month. Market cap is $370.65M, with 8.4 days to cover in short interest.

Canonical: https://massive.com/quote/crmd
Data as of: 2026-11-17T00:30:04.893Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$4.82** +0.16 (+3.43%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$4.85** +0.03 (+0.62%)
As of 7:30:04 PM EST on Nov 16, 2026 · After hours

## Stock performance

How CorMedix Inc. (CRMD) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +3.43% |
| 1W | -11.88% |
| 1M | -33.61% |
| YTD | -58.56% |
| 1Y | -52.16% |
| 52-wk range | $4.65 – $13.02 |

From daily closes through Nov 16, 2026.

## Key statistics

Today's trading snapshot for CRMD: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $4.75 – $5.23 |
| Open | $5.05 |
| Prev close | $4.66 |
| Volume | 3.2M |
| Market cap | $370.65M |
| Shares out | 79.54M |

## Valuation and profitability ratios

Valuation and profitability ratios for CorMedix Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 1.98 |
| P/S | 0.80 |
| P/B | 0.80 |
| P/FCF | 1.48 |
| ROE | 40.6% |
| ROA | 20.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[CorMedix Inc. (CRMD) insider trading](https://massive.com/quote/crmd/insider-trading.md): open-market Form 4 buys and sells by CorMedix Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events CorMedix Inc. has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, CorMedix Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Nov 10, 2026 · Investor presentation
  “In connection with the announcement, the Company hosted a conference call and webcast for investors on November 9, 2026, and made available an investor presentation regarding the transaction.”
- Nov 9, 2026 · Acquisition consideration shares
  “As consideration for the Asset Sale, the Company has agreed to (i) issue to the Seller 14,583,333 shares of the Company's common stock ... (ii) pay to the Seller a purchase price equal to $145.0 million in cash ... \[and\] (iv) pay to the Seller earn-out payments of $25.0 million ... and an additional $30.0 million ... payable at the Company's election in cash, shares of Common Stock or a combination thereof.”
- Nov 2, 2026 · Business update
  “On November 2, 2026, the Company issued a press release providing a business update and announcing the Company's cash position for the quarter ended September 30, 2026.”
- Oct 19, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On October 19, 2026, CorMedix, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease.”

## Dividend history and stock splits

CorMedix Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-5 · Mar 26, 2019

## CRMD short interest

How heavily CRMD is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.4 |
| Short interest | 14.21M |
| Avg volume | 1.68M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## CRMD news

The latest news and headlines about CorMedix Inc. (CRMD).

- [CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates](https://www.zacks.com/stock/news/3028452/cormedix-crmd-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3028452) · Zacks Investment Research · Nov 12, 2026 · neutral sentiment
- [Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3027563/kura-oncology-kura-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3027563) · Zacks Investment Research · Nov 10, 2026 · neutral sentiment
- [Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?](https://www.zacks.com/stock/news/3026495/immatics-imtx-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3026495) · Zacks Investment Research · Nov 9, 2026 · positive sentiment
- [Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline](https://www.zacks.com/stock/news/3023072/earnings-preview-cormedix-crmd-q3-earnings-expected-to-decline?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3023072) · Zacks Investment Research · Nov 4, 2026 · negative sentiment
- [CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?](https://www.zacks.com/stock/news/3002995/crmd-vs-prta-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-fundamental_analysis|yseop_template_3-3002995) · Zacks Investment Research · Oct 8, 2026 · positive sentiment

## About CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 191 |
| Listed | May 13, 2010 |

[Company website](https://www.cormedix.com)

## FAQ

### What is the CorMedix Inc. (CRMD) stock price today?

CorMedix Inc. (CRMD) is trading at $4.82 (+3.43% on the day) as of 7:30:04 PM EST on Nov 16, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is CorMedix Inc.?

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets.

### What is the short interest in CRMD?

As of Oct 30, 2026, CRMD has 14.21M shares short and 8.4 days to cover.

### What exchange is CRMD listed on?

CorMedix Inc. (CRMD) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time CRMD quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=CRMD`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [CorMedix Inc. (CRMD) insider trading](https://massive.com/quote/crmd/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
